Item 8.01. Other Events.

On January 27, 2020, Sorrento Therapeutics, Inc. (the "Company") issued a press release announcing that its Board of Directors has unanimously rejected the non-binding proposal the Company received on January 9, 2020 to acquire a majority or all of the issued and outstanding shares of the Company for up to $7.00 per share. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

On January 27, 2020, the Company issued an additional press release announcing the positive results of multiple resiniferatoxin (RTX) pre-pivotal (phase 1b/2) clinical studies, which will be presented at two upcoming pain conferences. A copy of the press release is filed herewith as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibit.



  99.1     Press Release regarding rejection of acquisition proposal, dated
         January 27, 2020.
           Press Release regarding positive results of resiniferatoxin (RTX)
  99.2   pre-pivotal (phase 1b/2) clinical studies, dated January 27, 2020.

© Edgar Online, source Glimpses